Schaeffer's Top Stock Picks for '25

Call Players Take Aim at Tanking Amicus Therapeutics, Inc. (FOLD)

Amicus Therapeutics, Inc. (FOLD) is short-sale restricted, after the company announced a delay on its migalastat new drug application

Oct 2, 2015 at 11:33 AM
facebook X logo linkedin


Amicus Therapeutics, Inc. (NASDAQ:FOLD) is among the biggest losers on the Nasdaq, after the company said its new drug application (NDA) for its experimental migalastat treatment likely won't be submitted to the Food and Drug Administration (FDA) by year-end. At last check, the shares have tanked 40% at $8.23, and have landed on the short-sale restricted list. Meanwhile, activity has spiked in the stock's options pits.

Most notably, FOLD call volume is running at 21 times the normal intraday rate, and about 3.5 times the pace of puts. The most active option is the now out-of-the-money January 2016 10-strike call, where 2,000 contracts are on the tape -- half of which transpired as a block.

This represents a departure from the longer-term put-skewed trend. Specifically, FOLD's 10-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.90 ranks in the 82nd percentile of its annual range. In other words, traders have been buying to open bearish bets over bullish at a faster-than-usual clip of late.

On the flip side, the brokerage bunch has taken a shine to Amicus Therapeutics, Inc. (NASDAQ:FOLD). Three-quarters of analysts have doled out "strong buy" endorsements on the stock, while its consensus 12-month price target of $23.10 nearly triples the current perch (and would mark record-high levels). If today's disappointing news -- and resultant bear gap -- prompt a round of downgrades and/or price-target cuts, FOLD could face even more pressure.
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?

 

 

(function(doc, script) { var js, fjs = doc.getElementsByTagName(script)[0], frag = doc.createDocumentFragment(), add = function(url, id) { if (doc.getElementById(id)) {return;} js = doc.createElement(script); js.src = url; id && (js.id = id); frag.appendChild( js ); }; // Google+ button //add('https://apis.google.com/js/platform.js', async="defer"); // Facebook SDK add('//connect.facebook.net/en_US/all.js#xfbml=1&appId=772755279557744', 'facebook-jssdk'); // Twitter SDK //add('//platform.twitter.com/widgets.js', charset='utf-8'); fjs.parentNode.insertBefore(frag, fjs); }(document, 'script'));